nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0657	0.463	CbGbCtD
Everolimus—CYP3A4—Progesterone—uterine cancer	0.0435	0.306	CbGbCtD
Everolimus—CYP3A4—Etoposide—uterine cancer	0.0195	0.137	CbGbCtD
Everolimus—CYP3A4—Doxorubicin—uterine cancer	0.0133	0.0935	CbGbCtD
Everolimus—MTOR—myometrium—uterine cancer	0.0082	0.0641	CbGeAlD
Everolimus—FKBP1A—myometrium—uterine cancer	0.00737	0.0577	CbGeAlD
Everolimus—MTOR—epithelium—uterine cancer	0.00644	0.0503	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—uterine cancer	0.0062	0.0485	CbGeAlD
Everolimus—MTOR—renal system—uterine cancer	0.00597	0.0467	CbGeAlD
Everolimus—FKBP1A—epithelium—uterine cancer	0.00579	0.0453	CbGeAlD
Everolimus—MTOR—endometrium—uterine cancer	0.00577	0.0452	CbGeAlD
Everolimus—FKBP1A—uterine cervix—uterine cancer	0.00574	0.0449	CbGeAlD
Everolimus—MTOR—mammalian vulva—uterine cancer	0.00558	0.0437	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—uterine cancer	0.00558	0.0436	CbGeAlD
Everolimus—FKBP1A—decidua—uterine cancer	0.00547	0.0428	CbGeAlD
Everolimus—FKBP1A—renal system—uterine cancer	0.00537	0.042	CbGeAlD
Everolimus—MTOR—uterus—uterine cancer	0.00532	0.0416	CbGeAlD
Everolimus—FKBP1A—endometrium—uterine cancer	0.00519	0.0406	CbGeAlD
Everolimus—FKBP1A—mammalian vulva—uterine cancer	0.00502	0.0393	CbGeAlD
Everolimus—FKBP1A—uterus—uterine cancer	0.00478	0.0374	CbGeAlD
Everolimus—MTOR—female reproductive system—uterine cancer	0.00478	0.0374	CbGeAlD
Everolimus—MTOR—female gonad—uterine cancer	0.00435	0.034	CbGeAlD
Everolimus—MTOR—vagina—uterine cancer	0.00432	0.0338	CbGeAlD
Everolimus—FKBP1A—female reproductive system—uterine cancer	0.0043	0.0336	CbGeAlD
Everolimus—FKBP1A—female gonad—uterine cancer	0.00391	0.0306	CbGeAlD
Everolimus—FKBP1A—vagina—uterine cancer	0.00389	0.0304	CbGeAlD
Everolimus—MTOR—lymph node—uterine cancer	0.0028	0.0219	CbGeAlD
Everolimus—FKBP1A—lymph node—uterine cancer	0.00252	0.0197	CbGeAlD
Everolimus—CYP3A4—renal system—uterine cancer	0.00175	0.0137	CbGeAlD
Everolimus—CYP3A4—female reproductive system—uterine cancer	0.00141	0.011	CbGeAlD
Everolimus—Influenza—Epirubicin—uterine cancer	0.000231	0.000482	CcSEcCtD
Everolimus—Dysphagia—Epirubicin—uterine cancer	0.000231	0.000482	CcSEcCtD
Everolimus—Dehydration—Doxorubicin—uterine cancer	0.00023	0.00048	CcSEcCtD
Everolimus—Thrombocytopenia—Etoposide—uterine cancer	0.00023	0.000479	CcSEcCtD
Everolimus—Tachycardia—Etoposide—uterine cancer	0.000229	0.000477	CcSEcCtD
Everolimus—Liver function test abnormal—Doxorubicin—uterine cancer	0.000228	0.000476	CcSEcCtD
Everolimus—Skin disorder—Etoposide—uterine cancer	0.000228	0.000475	CcSEcCtD
Everolimus—Dry skin—Doxorubicin—uterine cancer	0.000227	0.000473	CcSEcCtD
Everolimus—Hyperhidrosis—Etoposide—uterine cancer	0.000227	0.000473	CcSEcCtD
Everolimus—Pancreatitis—Epirubicin—uterine cancer	0.000227	0.000472	CcSEcCtD
Everolimus—Abdominal pain upper—Doxorubicin—uterine cancer	0.000226	0.000471	CcSEcCtD
Everolimus—Hypokalaemia—Doxorubicin—uterine cancer	0.000225	0.000469	CcSEcCtD
Everolimus—Angina pectoris—Epirubicin—uterine cancer	0.000225	0.000469	CcSEcCtD
Everolimus—Breast disorder—Doxorubicin—uterine cancer	0.000224	0.000466	CcSEcCtD
Everolimus—Anorexia—Etoposide—uterine cancer	0.000224	0.000466	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000223	0.000465	CcSEcCtD
Everolimus—Bronchitis—Epirubicin—uterine cancer	0.000222	0.000463	CcSEcCtD
Everolimus—Diarrhoea—Dactinomycin—uterine cancer	0.000222	0.000462	CcSEcCtD
Everolimus—Nasopharyngitis—Doxorubicin—uterine cancer	0.000221	0.000461	CcSEcCtD
Everolimus—Pancytopenia—Epirubicin—uterine cancer	0.00022	0.000458	CcSEcCtD
Everolimus—Hypotension—Etoposide—uterine cancer	0.000219	0.000457	CcSEcCtD
Everolimus—Gastritis—Doxorubicin—uterine cancer	0.000219	0.000457	CcSEcCtD
Everolimus—Muscular weakness—Doxorubicin—uterine cancer	0.000218	0.000455	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000218	0.000455	CcSEcCtD
Everolimus—Dysuria—Epirubicin—uterine cancer	0.000216	0.000451	CcSEcCtD
Everolimus—Neutropenia—Epirubicin—uterine cancer	0.000216	0.000451	CcSEcCtD
Everolimus—Abdominal distension—Doxorubicin—uterine cancer	0.000215	0.000449	CcSEcCtD
Everolimus—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000215	0.000448	CcSEcCtD
Everolimus—Influenza—Doxorubicin—uterine cancer	0.000214	0.000446	CcSEcCtD
Everolimus—Dysphagia—Doxorubicin—uterine cancer	0.000214	0.000446	CcSEcCtD
Everolimus—Pollakiuria—Epirubicin—uterine cancer	0.000214	0.000445	CcSEcCtD
Everolimus—Paraesthesia—Etoposide—uterine cancer	0.000211	0.000439	CcSEcCtD
Everolimus—Pancreatitis—Doxorubicin—uterine cancer	0.00021	0.000437	CcSEcCtD
Everolimus—Weight decreased—Epirubicin—uterine cancer	0.000209	0.000436	CcSEcCtD
Everolimus—Dyspnoea—Etoposide—uterine cancer	0.000209	0.000436	CcSEcCtD
Everolimus—Hyperglycaemia—Epirubicin—uterine cancer	0.000209	0.000435	CcSEcCtD
Everolimus—Somnolence—Etoposide—uterine cancer	0.000208	0.000435	CcSEcCtD
Everolimus—Angina pectoris—Doxorubicin—uterine cancer	0.000208	0.000434	CcSEcCtD
Everolimus—Pneumonia—Epirubicin—uterine cancer	0.000207	0.000432	CcSEcCtD
Everolimus—Infestation—Epirubicin—uterine cancer	0.000206	0.00043	CcSEcCtD
Everolimus—Infestation NOS—Epirubicin—uterine cancer	0.000206	0.00043	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—uterine cancer	0.000206	0.000429	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—uterine cancer	0.000206	0.000429	CcSEcCtD
Everolimus—Rash—Dactinomycin—uterine cancer	0.000204	0.000426	CcSEcCtD
Everolimus—Decreased appetite—Etoposide—uterine cancer	0.000204	0.000425	CcSEcCtD
Everolimus—Pancytopenia—Doxorubicin—uterine cancer	0.000203	0.000423	CcSEcCtD
Everolimus—Renal failure—Epirubicin—uterine cancer	0.000203	0.000422	CcSEcCtD
Everolimus—Gastrointestinal disorder—Etoposide—uterine cancer	0.000202	0.000422	CcSEcCtD
Everolimus—Fatigue—Etoposide—uterine cancer	0.000202	0.000421	CcSEcCtD
Everolimus—Jaundice—Epirubicin—uterine cancer	0.000201	0.000419	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—uterine cancer	0.000201	0.000419	CcSEcCtD
Everolimus—Constipation—Etoposide—uterine cancer	0.000201	0.000418	CcSEcCtD
Everolimus—Pain—Etoposide—uterine cancer	0.000201	0.000418	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—uterine cancer	0.0002	0.000418	CcSEcCtD
Everolimus—Conjunctivitis—Epirubicin—uterine cancer	0.0002	0.000418	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—uterine cancer	0.0002	0.000417	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—uterine cancer	0.0002	0.000417	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000199	0.000414	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—uterine cancer	0.000198	0.000412	CcSEcCtD
Everolimus—Haematuria—Epirubicin—uterine cancer	0.000197	0.00041	CcSEcCtD
Everolimus—Hepatobiliary disease—Epirubicin—uterine cancer	0.000195	0.000406	CcSEcCtD
Everolimus—Epistaxis—Epirubicin—uterine cancer	0.000194	0.000405	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—uterine cancer	0.000194	0.000403	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—uterine cancer	0.000193	0.000403	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—uterine cancer	0.000193	0.000403	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—uterine cancer	0.000193	0.000402	CcSEcCtD
Everolimus—Nausea—Dactinomycin—uterine cancer	0.000192	0.000401	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—uterine cancer	0.000192	0.0004	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—uterine cancer	0.000192	0.0004	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—uterine cancer	0.000191	0.000764	CbGpPWpGaD
Everolimus—Infestation—Doxorubicin—uterine cancer	0.000191	0.000398	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—uterine cancer	0.000191	0.000398	CcSEcCtD
Everolimus—MTOR—PI3K/AKT activation—AKT1—uterine cancer	0.000189	0.000754	CbGpPWpGaD
Everolimus—Renal failure—Doxorubicin—uterine cancer	0.000187	0.000391	CcSEcCtD
Everolimus—MTOR—GAB1 signalosome—AKT1—uterine cancer	0.000187	0.000748	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—uterine cancer	0.000187	0.000745	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—uterine cancer	0.000187	0.000745	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—uterine cancer	0.000187	0.000745	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—uterine cancer	0.000186	0.000744	CbGpPWpGaD
Everolimus—Haemoglobin—Epirubicin—uterine cancer	0.000186	0.000388	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—uterine cancer	0.000186	0.000387	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—uterine cancer	0.000186	0.000387	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—uterine cancer	0.000185	0.000387	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—uterine cancer	0.000185	0.000386	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—uterine cancer	0.000185	0.000386	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—uterine cancer	0.000185	0.000386	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—uterine cancer	0.000185	0.000386	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—uterine cancer	0.000185	0.00074	CbGpPWpGaD
Everolimus—Hepatitis—Epirubicin—uterine cancer	0.000185	0.000386	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—uterine cancer	0.000185	0.000386	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—NRAS—uterine cancer	0.000185	0.000738	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	0.000184	0.000737	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—uterine cancer	0.000184	0.000736	CbGpPWpGaD
Everolimus—Hypoaesthesia—Epirubicin—uterine cancer	0.000184	0.000384	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—uterine cancer	0.000184	0.000383	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—uterine cancer	0.000183	0.000732	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—uterine cancer	0.000183	0.000731	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—AKT1—uterine cancer	0.000183	0.000731	CbGpPWpGaD
Everolimus—Urinary tract disorder—Epirubicin—uterine cancer	0.000183	0.000381	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—NRAS—uterine cancer	0.000182	0.000729	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	0.000182	0.000728	CbGpPWpGaD
Everolimus—Oedema peripheral—Epirubicin—uterine cancer	0.000182	0.00038	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000182	0.000727	CbGpPWpGaD
Everolimus—Haematuria—Doxorubicin—uterine cancer	0.000182	0.000379	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—uterine cancer	0.000182	0.000379	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—uterine cancer	0.000181	0.000378	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—KRAS—uterine cancer	0.000181	0.000724	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Doxorubicin—uterine cancer	0.00018	0.000376	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—uterine cancer	0.00018	0.00072	CbGpPWpGaD
Everolimus—Epistaxis—Doxorubicin—uterine cancer	0.00018	0.000375	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—uterine cancer	0.000179	0.000373	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—AKR1B10—uterine cancer	0.000179	0.000714	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PIK3CA—uterine cancer	0.000177	0.000707	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SOCS3—uterine cancer	0.000175	0.000698	CbGpPWpGaD
Everolimus—MTOR—Disease—AKR1C1—uterine cancer	0.000174	0.000696	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KRAS—uterine cancer	0.000173	0.000692	CbGpPWpGaD
Everolimus—Eye disorder—Epirubicin—uterine cancer	0.000173	0.00036	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—uterine cancer	0.000173	0.00036	CcSEcCtD
Everolimus—MTOR—B Cell Activation—NRAS—uterine cancer	0.000173	0.000689	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—uterine cancer	0.000172	0.000688	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—uterine cancer	0.000172	0.000688	CbGpPWpGaD
Everolimus—Haemoglobin—Doxorubicin—uterine cancer	0.000172	0.000359	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000172	0.000686	CbGpPWpGaD
Everolimus—Cardiac disorder—Epirubicin—uterine cancer	0.000172	0.000358	CcSEcCtD
Everolimus—Flushing—Epirubicin—uterine cancer	0.000172	0.000358	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—uterine cancer	0.000172	0.000358	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—KRAS—uterine cancer	0.000171	0.000685	CbGpPWpGaD
Everolimus—Hepatitis—Doxorubicin—uterine cancer	0.000171	0.000357	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—uterine cancer	0.000171	0.000357	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—KRAS—uterine cancer	0.000171	0.000682	CbGpPWpGaD
Everolimus—Hypoaesthesia—Doxorubicin—uterine cancer	0.00017	0.000355	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—AKT1—uterine cancer	0.00017	0.000679	CbGpPWpGaD
Everolimus—Pharyngitis—Doxorubicin—uterine cancer	0.00017	0.000354	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—uterine cancer	0.000169	0.000676	CbGpPWpGaD
Everolimus—Urinary tract disorder—Doxorubicin—uterine cancer	0.000169	0.000352	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CXCL8—uterine cancer	0.000169	0.000674	CbGpPWpGaD
Everolimus—Oedema peripheral—Doxorubicin—uterine cancer	0.000169	0.000352	CcSEcCtD
Everolimus—Asthenia—Etoposide—uterine cancer	0.000168	0.000351	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—uterine cancer	0.000168	0.000351	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—uterine cancer	0.000168	0.000672	CbGpPWpGaD
Everolimus—Angiopathy—Epirubicin—uterine cancer	0.000168	0.00035	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—uterine cancer	0.000168	0.00035	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—uterine cancer	0.000167	0.000348	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—ERBB2—uterine cancer	0.000167	0.000667	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKR1C3—uterine cancer	0.000167	0.000667	CbGpPWpGaD
Everolimus—Mediastinal disorder—Epirubicin—uterine cancer	0.000167	0.000348	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—PIK3CA—uterine cancer	0.000167	0.000665	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN2B—uterine cancer	0.000167	0.000665	CbGpPWpGaD
Everolimus—Chills—Epirubicin—uterine cancer	0.000166	0.000346	CcSEcCtD
Everolimus—Pruritus—Etoposide—uterine cancer	0.000166	0.000346	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—uterine cancer	0.000165	0.00066	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN1B—uterine cancer	0.000165	0.000659	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—uterine cancer	0.000164	0.000654	CbGpPWpGaD
Everolimus—Alopecia—Epirubicin—uterine cancer	0.000164	0.000341	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PGR—uterine cancer	0.000163	0.00065	CbGpPWpGaD
Everolimus—Mental disorder—Epirubicin—uterine cancer	0.000162	0.000338	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—uterine cancer	0.000162	0.000647	CbGpPWpGaD
Everolimus—Malnutrition—Epirubicin—uterine cancer	0.000161	0.000336	CcSEcCtD
Everolimus—Erythema—Epirubicin—uterine cancer	0.000161	0.000336	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—HRAS—uterine cancer	0.000161	0.000643	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—uterine cancer	0.000161	0.000641	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—uterine cancer	0.000161	0.000641	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—uterine cancer	0.000161	0.000641	CbGpPWpGaD
Everolimus—Diarrhoea—Etoposide—uterine cancer	0.00016	0.000334	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—uterine cancer	0.00016	0.000333	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—PIK3CA—uterine cancer	0.00016	0.000639	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—PIK3CA—uterine cancer	0.000159	0.000635	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KRAS—uterine cancer	0.000159	0.000635	CbGpPWpGaD
Everolimus—Cardiac disorder—Doxorubicin—uterine cancer	0.000159	0.000331	CcSEcCtD
Everolimus—Flushing—Doxorubicin—uterine cancer	0.000159	0.000331	CcSEcCtD
Everolimus—Flatulence—Epirubicin—uterine cancer	0.000159	0.000331	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—PIK3CA—uterine cancer	0.000158	0.000632	CbGpPWpGaD
Everolimus—Dysgeusia—Epirubicin—uterine cancer	0.000158	0.000329	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—uterine cancer	0.000158	0.00063	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—PIK3CA—uterine cancer	0.000158	0.000629	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KRAS—uterine cancer	0.000157	0.000627	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—PIK3CA—uterine cancer	0.000157	0.000626	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—uterine cancer	0.000157	0.000626	CbGpPWpGaD
Everolimus—Back pain—Epirubicin—uterine cancer	0.000156	0.000325	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—uterine cancer	0.000155	0.000324	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—YWHAE—uterine cancer	0.000155	0.00062	CbGpPWpGaD
Everolimus—Dizziness—Etoposide—uterine cancer	0.000155	0.000323	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—uterine cancer	0.000155	0.000323	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—CDKN1B—uterine cancer	0.000155	0.000618	CbGpPWpGaD
Everolimus—Immune system disorder—Doxorubicin—uterine cancer	0.000155	0.000322	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—uterine cancer	0.000154	0.000617	CbGpPWpGaD
Everolimus—Mediastinal disorder—Doxorubicin—uterine cancer	0.000154	0.000322	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—HRAS—uterine cancer	0.000154	0.000616	CbGpPWpGaD
Everolimus—Chills—Doxorubicin—uterine cancer	0.000154	0.00032	CcSEcCtD
Everolimus—FKBP1A—Disease—SMAD3—uterine cancer	0.000152	0.000607	CbGpPWpGaD
Everolimus—Vision blurred—Epirubicin—uterine cancer	0.000152	0.000316	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FGFR2—uterine cancer	0.000152	0.000606	CbGpPWpGaD
Everolimus—Alopecia—Doxorubicin—uterine cancer	0.000151	0.000315	CcSEcCtD
Everolimus—MTOR—Disease—DCN—uterine cancer	0.000151	0.000602	CbGpPWpGaD
Everolimus—Mental disorder—Doxorubicin—uterine cancer	0.00015	0.000313	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—uterine cancer	0.000149	0.000312	CcSEcCtD
Everolimus—Vomiting—Etoposide—uterine cancer	0.000149	0.000311	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—uterine cancer	0.000149	0.000311	CcSEcCtD
Everolimus—Erythema—Doxorubicin—uterine cancer	0.000149	0.000311	CcSEcCtD
Everolimus—Anaemia—Epirubicin—uterine cancer	0.000149	0.00031	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FBXW7—uterine cancer	0.000149	0.000595	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KRAS—uterine cancer	0.000149	0.000593	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RNF43—uterine cancer	0.000148	0.000592	CbGpPWpGaD
Everolimus—Agitation—Epirubicin—uterine cancer	0.000148	0.000309	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—HRAS—uterine cancer	0.000148	0.000591	CbGpPWpGaD
Everolimus—Rash—Etoposide—uterine cancer	0.000148	0.000308	CcSEcCtD
Everolimus—Dermatitis—Etoposide—uterine cancer	0.000148	0.000308	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—PIK3CA—uterine cancer	0.000147	0.000589	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PIK3CA—uterine cancer	0.000147	0.000589	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—uterine cancer	0.000147	0.000589	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—uterine cancer	0.000147	0.000588	CbGpPWpGaD
Everolimus—Headache—Etoposide—uterine cancer	0.000147	0.000306	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—uterine cancer	0.000147	0.000306	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—HRAS—uterine cancer	0.000146	0.000585	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—uterine cancer	0.000146	0.000585	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PIK3CA—uterine cancer	0.000146	0.000584	CbGpPWpGaD
Everolimus—Dysgeusia—Doxorubicin—uterine cancer	0.000146	0.000304	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—HRAS—uterine cancer	0.000146	0.000582	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR2—uterine cancer	0.000146	0.000582	CbGpPWpGaD
Everolimus—Malaise—Epirubicin—uterine cancer	0.000145	0.000303	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—HRAS—uterine cancer	0.000145	0.000579	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR2—uterine cancer	0.000145	0.000579	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—uterine cancer	0.000145	0.000579	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—EP300—uterine cancer	0.000145	0.000578	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—uterine cancer	0.000145	0.000577	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRF1—uterine cancer	0.000144	0.000577	CbGpPWpGaD
Everolimus—Syncope—Epirubicin—uterine cancer	0.000144	0.000301	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—PIK3CA—uterine cancer	0.000144	0.000576	CbGpPWpGaD
Everolimus—Leukopenia—Epirubicin—uterine cancer	0.000144	0.000301	CcSEcCtD
Everolimus—Back pain—Doxorubicin—uterine cancer	0.000144	0.0003	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—uterine cancer	0.000143	0.000299	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—uterine cancer	0.000143	0.000571	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PTEN—uterine cancer	0.000142	0.000569	CbGpPWpGaD
Everolimus—Palpitations—Epirubicin—uterine cancer	0.000142	0.000297	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	0.000142	0.000568	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—uterine cancer	0.000142	0.000568	CbGpPWpGaD
Everolimus—Loss of consciousness—Epirubicin—uterine cancer	0.000142	0.000295	CcSEcCtD
Everolimus—Cough—Epirubicin—uterine cancer	0.000141	0.000293	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—uterine cancer	0.00014	0.000293	CcSEcCtD
Everolimus—FKBP1A—Disease—MTHFR—uterine cancer	0.00014	0.000558	CbGpPWpGaD
Everolimus—Convulsion—Epirubicin—uterine cancer	0.00014	0.000291	CcSEcCtD
Everolimus—Nausea—Etoposide—uterine cancer	0.000139	0.00029	CcSEcCtD
Everolimus—Hypertension—Epirubicin—uterine cancer	0.000139	0.00029	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—uterine cancer	0.000138	0.000288	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—uterine cancer	0.000138	0.000552	CbGpPWpGaD
Everolimus—Anaemia—Doxorubicin—uterine cancer	0.000138	0.000287	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—uterine cancer	0.000137	0.000548	CbGpPWpGaD
Everolimus—Myalgia—Epirubicin—uterine cancer	0.000137	0.000286	CcSEcCtD
Everolimus—Chest pain—Epirubicin—uterine cancer	0.000137	0.000286	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—uterine cancer	0.000137	0.000286	CcSEcCtD
Everolimus—Agitation—Doxorubicin—uterine cancer	0.000137	0.000285	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	0.000137	0.000546	CbGpPWpGaD
Everolimus—Anxiety—Epirubicin—uterine cancer	0.000137	0.000285	CcSEcCtD
Everolimus—MTOR—B Cell Activation—PIK3CA—uterine cancer	0.000136	0.000545	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—uterine cancer	0.000136	0.000545	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—uterine cancer	0.000136	0.000545	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—uterine cancer	0.000136	0.000545	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000136	0.000284	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—AKT1—uterine cancer	0.000136	0.000544	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	0.000136	0.000542	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INHBA—uterine cancer	0.000135	0.000541	CbGpPWpGaD
Everolimus—Discomfort—Epirubicin—uterine cancer	0.000135	0.000282	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—HRAS—uterine cancer	0.000135	0.00054	CbGpPWpGaD
Everolimus—Malaise—Doxorubicin—uterine cancer	0.000134	0.00028	CcSEcCtD
Everolimus—MTOR—Disease—AKR1C3—uterine cancer	0.000134	0.000536	CbGpPWpGaD
Everolimus—Dry mouth—Epirubicin—uterine cancer	0.000134	0.00028	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—uterine cancer	0.000134	0.000535	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.000134	0.000535	CbGpPWpGaD
Everolimus—Syncope—Doxorubicin—uterine cancer	0.000134	0.000279	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—HRAS—uterine cancer	0.000133	0.000533	CbGpPWpGaD
Everolimus—Leukopenia—Doxorubicin—uterine cancer	0.000133	0.000278	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—uterine cancer	0.000132	0.000275	CcSEcCtD
Everolimus—Oedema—Epirubicin—uterine cancer	0.000131	0.000274	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—uterine cancer	0.000131	0.000273	CcSEcCtD
Everolimus—MTOR—Disease—HMGA1—uterine cancer	0.000131	0.000522	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	0.000131	0.000522	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—uterine cancer	0.000131	0.000522	CbGpPWpGaD
Everolimus—Infection—Epirubicin—uterine cancer	0.000131	0.000272	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—STK11—uterine cancer	0.00013	0.00052	CbGpPWpGaD
Everolimus—Cough—Doxorubicin—uterine cancer	0.00013	0.000271	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—AKT1—uterine cancer	0.00013	0.000519	CbGpPWpGaD
Everolimus—MTOR—Immune System—FBXW7—uterine cancer	0.000129	0.000517	CbGpPWpGaD
Everolimus—Shock—Epirubicin—uterine cancer	0.000129	0.00027	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	0.000129	0.000517	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—uterine cancer	0.000129	0.000517	CbGpPWpGaD
Everolimus—Convulsion—Doxorubicin—uterine cancer	0.000129	0.000269	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—uterine cancer	0.000129	0.000269	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—uterine cancer	0.000129	0.000268	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—AKT1—uterine cancer	0.000129	0.000514	CbGpPWpGaD
Everolimus—Hypertension—Doxorubicin—uterine cancer	0.000129	0.000268	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—uterine cancer	0.000128	0.000267	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—AKT1—uterine cancer	0.000128	0.000512	CbGpPWpGaD
Everolimus—Skin disorder—Epirubicin—uterine cancer	0.000128	0.000266	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—uterine cancer	0.000127	0.000265	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—NRAS—uterine cancer	0.000127	0.000507	CbGpPWpGaD
Everolimus—Myalgia—Doxorubicin—uterine cancer	0.000127	0.000264	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—uterine cancer	0.000127	0.000264	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—uterine cancer	0.000127	0.000264	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—uterine cancer	0.000126	0.000264	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—uterine cancer	0.000126	0.000504	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—uterine cancer	0.000126	0.000504	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000126	0.000263	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—uterine cancer	0.000125	0.000261	CcSEcCtD
Everolimus—Anorexia—Epirubicin—uterine cancer	0.000125	0.000261	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—uterine cancer	0.000124	0.000259	CcSEcCtD
Everolimus—Hypotension—Epirubicin—uterine cancer	0.000123	0.000256	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—AKR1C1—uterine cancer	0.000122	0.000487	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SOCS3—uterine cancer	0.000122	0.000487	CbGpPWpGaD
Everolimus—Oedema—Doxorubicin—uterine cancer	0.000122	0.000254	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	0.000121	0.000483	CbGpPWpGaD
Everolimus—Infection—Doxorubicin—uterine cancer	0.000121	0.000252	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—AKT1—uterine cancer	0.00012	0.000481	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—uterine cancer	0.00012	0.000481	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	0.00012	0.000481	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00012	0.00025	CcSEcCtD
Everolimus—Shock—Doxorubicin—uterine cancer	0.00012	0.000249	CcSEcCtD
Everolimus—MTOR—Disease—FBXW7—uterine cancer	0.00012	0.000477	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—uterine cancer	0.000119	0.000477	CbGpPWpGaD
Everolimus—Nervous system disorder—Doxorubicin—uterine cancer	0.000119	0.000249	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—uterine cancer	0.000119	0.000248	CcSEcCtD
Everolimus—Insomnia—Epirubicin—uterine cancer	0.000119	0.000248	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—uterine cancer	0.000119	0.000247	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—uterine cancer	0.000118	0.000473	CbGpPWpGaD
Everolimus—Skin disorder—Doxorubicin—uterine cancer	0.000118	0.000246	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—uterine cancer	0.000118	0.000246	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—AKT1—uterine cancer	0.000118	0.000471	CbGpPWpGaD
Everolimus—Hyperhidrosis—Doxorubicin—uterine cancer	0.000118	0.000245	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—uterine cancer	0.000117	0.000244	CcSEcCtD
Everolimus—Somnolence—Epirubicin—uterine cancer	0.000117	0.000244	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CDKN2B—uterine cancer	0.000117	0.000466	CbGpPWpGaD
Everolimus—Anorexia—Doxorubicin—uterine cancer	0.000116	0.000242	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—uterine cancer	0.000116	0.000241	CcSEcCtD
Everolimus—Decreased appetite—Epirubicin—uterine cancer	0.000114	0.000238	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—uterine cancer	0.000114	0.000237	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000113	0.000237	CcSEcCtD
Everolimus—Fatigue—Epirubicin—uterine cancer	0.000113	0.000236	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IGF1R—uterine cancer	0.000113	0.000452	CbGpPWpGaD
Everolimus—Pain—Epirubicin—uterine cancer	0.000112	0.000234	CcSEcCtD
Everolimus—Constipation—Epirubicin—uterine cancer	0.000112	0.000234	CcSEcCtD
Everolimus—MTOR—B Cell Activation—AKT1—uterine cancer	0.000111	0.000445	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000111	0.000231	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—uterine cancer	0.00011	0.000229	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KRAS—uterine cancer	0.000109	0.000437	CbGpPWpGaD
Everolimus—Paraesthesia—Doxorubicin—uterine cancer	0.000109	0.000228	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—uterine cancer	0.000108	0.000226	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CDH1—uterine cancer	0.000108	0.000433	CbGpPWpGaD
Everolimus—Feeling abnormal—Epirubicin—uterine cancer	0.000108	0.000226	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—uterine cancer	0.000108	0.000225	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—uterine cancer	0.000107	0.000224	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—uterine cancer	0.000107	0.000223	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	0.000107	0.000426	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMAD3—uterine cancer	0.000106	0.000425	CbGpPWpGaD
Everolimus—MTOR—Immune System—SOCS3—uterine cancer	0.000106	0.000423	CbGpPWpGaD
Everolimus—Decreased appetite—Doxorubicin—uterine cancer	0.000106	0.00022	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000105	0.000219	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—uterine cancer	0.000105	0.000219	CcSEcCtD
Everolimus—Pain—Doxorubicin—uterine cancer	0.000104	0.000217	CcSEcCtD
Everolimus—Constipation—Doxorubicin—uterine cancer	0.000104	0.000217	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—uterine cancer	0.000104	0.000217	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—uterine cancer	0.000104	0.000217	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—uterine cancer	0.000104	0.000414	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR2—uterine cancer	0.000102	0.000406	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—uterine cancer	0.0001	0.000401	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—uterine cancer	0.0001	0.000209	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—uterine cancer	9.95e-05	0.000207	CcSEcCtD
Everolimus—Hypersensitivity—Epirubicin—uterine cancer	9.69e-05	0.000202	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—uterine cancer	9.62e-05	0.0002	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—uterine cancer	9.62e-05	0.0002	CcSEcCtD
Everolimus—MTOR—Innate Immune System—ERBB2—uterine cancer	9.52e-05	0.00038	CbGpPWpGaD
Everolimus—Asthenia—Epirubicin—uterine cancer	9.43e-05	0.000197	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—AKR1C3—uterine cancer	9.39e-05	0.000375	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN2B—uterine cancer	9.37e-05	0.000374	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—uterine cancer	9.3e-05	0.000194	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—uterine cancer	9.29e-05	0.000371	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PGR—uterine cancer	9.15e-05	0.000366	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—uterine cancer	9.15e-05	0.000365	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—uterine cancer	9.11e-05	0.000364	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—uterine cancer	8.99e-05	0.000187	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—uterine cancer	8.96e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Immune System—FGFR2—uterine cancer	8.83e-05	0.000353	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1B—uterine cancer	8.82e-05	0.000352	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—YWHAE—uterine cancer	8.73e-05	0.000349	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—uterine cancer	8.73e-05	0.000182	CcSEcCtD
Everolimus—Dizziness—Epirubicin—uterine cancer	8.69e-05	0.000181	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ESR1—uterine cancer	8.69e-05	0.000347	CbGpPWpGaD
Everolimus—Pruritus—Doxorubicin—uterine cancer	8.61e-05	0.000179	CcSEcCtD
Everolimus—MTOR—Disease—SMAD3—uterine cancer	8.55e-05	0.000342	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—uterine cancer	8.47e-05	0.000338	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—uterine cancer	8.43e-05	0.000337	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FBXW7—uterine cancer	8.37e-05	0.000334	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—uterine cancer	8.36e-05	0.000174	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CTNNB1—uterine cancer	8.33e-05	0.000333	CbGpPWpGaD
Everolimus—Diarrhoea—Doxorubicin—uterine cancer	8.32e-05	0.000173	CcSEcCtD
Everolimus—Rash—Epirubicin—uterine cancer	8.29e-05	0.000173	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—uterine cancer	8.28e-05	0.000173	CcSEcCtD
Everolimus—Headache—Epirubicin—uterine cancer	8.24e-05	0.000172	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—AKT1—uterine cancer	8.21e-05	0.000328	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR2—uterine cancer	8.16e-05	0.000326	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—uterine cancer	8.12e-05	0.000324	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—uterine cancer	8.04e-05	0.000168	CcSEcCtD
Everolimus—FKBP1A—Disease—CTNNB1—uterine cancer	7.97e-05	0.000318	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—uterine cancer	7.85e-05	0.000314	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—uterine cancer	7.81e-05	0.000163	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PTEN—uterine cancer	7.8e-05	0.000312	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—uterine cancer	7.77e-05	0.00031	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EP300—uterine cancer	7.75e-05	0.000309	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—uterine cancer	7.73e-05	0.000161	CcSEcCtD
Everolimus—Rash—Doxorubicin—uterine cancer	7.67e-05	0.00016	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—uterine cancer	7.66e-05	0.00016	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCL2—uterine cancer	7.65e-05	0.000306	CbGpPWpGaD
Everolimus—Headache—Doxorubicin—uterine cancer	7.62e-05	0.000159	CcSEcCtD
Everolimus—FKBP1A—Disease—EP300—uterine cancer	7.41e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STK11—uterine cancer	7.32e-05	0.000292	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SRD5A2—uterine cancer	7.29e-05	0.000291	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NDUFB11—uterine cancer	7.29e-05	0.000291	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—uterine cancer	7.25e-05	0.000289	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—uterine cancer	7.22e-05	0.000151	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NRAS—uterine cancer	6.96e-05	0.000278	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—uterine cancer	6.93e-05	0.000277	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS3—uterine cancer	6.85e-05	0.000274	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—uterine cancer	6.58e-05	0.000263	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN2B—uterine cancer	6.56e-05	0.000262	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—uterine cancer	6.38e-05	0.000255	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1R—uterine cancer	6.37e-05	0.000254	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—uterine cancer	6.24e-05	0.000249	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—uterine cancer	6.05e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—uterine cancer	5.99e-05	0.000239	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD3—uterine cancer	5.99e-05	0.000239	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—uterine cancer	5.96e-05	0.000238	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—uterine cancer	5.91e-05	0.000236	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—uterine cancer	5.73e-05	0.000229	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR2—uterine cancer	5.71e-05	0.000228	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—uterine cancer	5.58e-05	0.000223	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—uterine cancer	5.55e-05	0.000222	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—uterine cancer	5.5e-05	0.00022	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—uterine cancer	5.48e-05	0.000219	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—uterine cancer	5.44e-05	0.000217	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—uterine cancer	5.3e-05	0.000212	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1B1—uterine cancer	5.27e-05	0.000211	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STAR—uterine cancer	5.27e-05	0.000211	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—uterine cancer	5.19e-05	0.000207	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—uterine cancer	5.14e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—uterine cancer	5.12e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—uterine cancer	5.09e-05	0.000203	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—uterine cancer	5.07e-05	0.000202	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—uterine cancer	4.91e-05	0.000196	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—uterine cancer	4.89e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—uterine cancer	4.85e-05	0.000194	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—uterine cancer	4.85e-05	0.000194	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—uterine cancer	4.74e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—uterine cancer	4.73e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—uterine cancer	4.68e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—uterine cancer	4.51e-05	0.00018	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—uterine cancer	4.49e-05	0.00018	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—uterine cancer	4.48e-05	0.000179	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—uterine cancer	4.48e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—uterine cancer	4.37e-05	0.000174	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—uterine cancer	4.3e-05	0.000172	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—uterine cancer	4.22e-05	0.000169	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—uterine cancer	4.18e-05	0.000167	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—uterine cancer	4.17e-05	0.000166	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POLD1—uterine cancer	4.14e-05	0.000165	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—uterine cancer	3.9e-05	0.000156	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C1—uterine cancer	3.87e-05	0.000155	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—uterine cancer	3.84e-05	0.000153	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—uterine cancer	3.71e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—uterine cancer	3.63e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—uterine cancer	3.59e-05	0.000143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—uterine cancer	3.55e-05	0.000142	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RRM2—uterine cancer	3.45e-05	0.000138	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—uterine cancer	3.4e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—uterine cancer	3.35e-05	0.000134	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DCN—uterine cancer	3.35e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—uterine cancer	3.34e-05	0.000133	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—uterine cancer	3.32e-05	0.000133	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP11A1—uterine cancer	3.15e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—uterine cancer	3.14e-05	0.000125	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—uterine cancer	3.13e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—uterine cancer	3.09e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—uterine cancer	3.08e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—uterine cancer	3.06e-05	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.98e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—uterine cancer	2.92e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—uterine cancer	2.85e-05	0.000114	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—uterine cancer	2.76e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—uterine cancer	2.73e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—uterine cancer	2.73e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—uterine cancer	2.52e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—uterine cancer	2.35e-05	9.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STK11—uterine cancer	2.32e-05	9.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.32e-05	9.27e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—uterine cancer	2.16e-05	8.62e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—uterine cancer	2.09e-05	8.34e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—uterine cancer	2e-05	7.97e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—uterine cancer	1.76e-05	7.04e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—uterine cancer	1.74e-05	6.97e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—uterine cancer	9.7e-06	3.88e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—uterine cancer	9.25e-06	3.7e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—uterine cancer	6.84e-06	2.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—uterine cancer	5.59e-06	2.23e-05	CbGpPWpGaD
